Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Size: px
Start display at page:

Download "Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)"

Transcription

1 Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit us online at: Q 1 Can we print and share the presentation with our colleagues? Yes. The PowerPoint presentation and clinical guidelines are available on the PCMCH website. We encourage you to share the on-line documents with your colleagues. Q 2 Q 3 What is the scope of the NS clinical practice guidelines? The NS guidelines were written to address the psychosocial needs of opioid dependent women during the preconception, antenatal and postpartum/post discharge stages as well as the assessment and treatment of infants born to these women. These guidelines focus on NS resulting from opioid dependence and do not address the management of NS resulting from the use of selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, barbiturates, ethanol, sedatives or hypnotics. What is the opinion on screening for drugs at the beginning of the pregnancy? Would this scare the mothers off before getting the prenatal care that they need? Health care providers should routinely ask all women of childbearing age about use of medicinal and non-medicinal substances including alcohol, opioids and other analgesics, selective serotonin reuptake inhibitors (SSRIs) and tobacco use. Routine universal screening by primary health care providers is important to normalize conversation about this important and sensitive topic. Pregnancy is a time when a woman is most willing to make lifestyle changes for the wellbeing of her baby, therefore assessment and counselling about substance use is important at this time. Harm reduction models of care promote positive change and even small changes should be celebrated as a means to empower these women. Q 4 Q 5 Why is contraceptive counselling important for women beginning a methadone maintenance program? Contraceptive counselling is essential to prevent unplanned pregnancy when a woman switches from short acting opioids, which suppress ovulation, to a long acting opioid such as methadone or burprenorphine. Has PCMCH thought about having a narcotic registry to provide data about narcotic use? The MOHLTC s Ontario Narcotic Strategy introduced legislation to support the development of the Neonatal bstinence Syndrome Webinar (Feb. 9 & March 30, 2012): Questions & nswers Page 1 of 5

2 Narcotics Monitoring System, expected to be operational in the spring of It will provide a database for the collection and storage of information on prescribing and dispensing activities relating to prescription narcotics and other controlled substances in Ontario. Q 6 Q 7 Q 8 Q 9 Q 10 Q 11 Q 12 Q 13 n increasing number of newborns are at risk of NS due to maternal SSRI/SNRI use. Does PCMCH plan to address this in the future? This will be considered in the future but is not part of PCMCH s work plan. How is withdrawal from methadone different than with oxycontin or other narcotics? Methadone is a long acting opioid and therefore has a longer half life than other narcotics. Symptoms of methadone withdrawal may not occur until hours after birth and can be delayed up to 4 weeks. In infants exhibiting withdrawal symptoms from Methadone after more than 30 days, are they actually withdrawing from Methadone or are there other issues at play? It is possible for Methadone withdrawal to be delayed until 30 days after birth. This would likely occur in babies who are particularly slow to metabolize methadone. nother factor that could affect this is the cessation of or reduction in breastfeeding. If there is no change in outcome in the newborn between Methadone dosages in women, is there a goal to decrease the dose during pregnancy? The goal during pregnancy is to maintain women on an appropriate dose that keeps them comfortable 24 hours per day. Based on a meta-analysis, the maternal methadone dose is not related to the severity of neonatal withdrawal. Therefore women should focus on achieving a dose that eliminates withdrawal symptoms and cravings (i.e. to maintain abstinence from other opioids and other illicit drugs). Reducing the dose is not needed, especially since methadone metabolism increases towards the third trimester and the dose will need to be increased in response to new onset of withdrawal symptoms. What is the incidence of drug addiction in adulthood when an infant with NS was exposed at birth, especially when removed from the maternal social situation? The incidence of NS was not as high 20 years ago as it is currently; therefore there is no conclusive evidence at present regarding long-term outcomes for these infants. There have been some studies in the United Kingdom looking at the impact of co-factors in children raised in foster homes. What are the special accommodations for burprenorphine for pregnant clients in regards to it being funded and/or prescribed? In Canada, Buprenorphine is only available through Health Canada s Special ccess program and only during pregnancy. If approved, it is sent to hospital pharmacies and then supplied either for inpatients or at outpatient clinic appointments. There is no cost for the patient. Can you recommend V resources for staff training purposes? The expert panel did not review training videos and therefore does not recommend a specific resource. What impact does substance use and NS have on Northern Ontario? Neonatal bstinence Syndrome Webinar (Feb. 9 & March 30, 2012): Questions & nswers Page 2 of 5

3 Q 14 Q 15 Q 16 Q 17 Q 18 Q 19 Q 20 The management of substance use and NS is particularly problematic in Northern Ontario. Many First Nations communities have identified a state of emergency regarding the abuse of prescription narcotics. The vast geographical area of the North encompasses multiple remote communities that rely on a nursing station for health care support with few, if any, local family physicians. They rely on distant regional hospitals for their acute healthcare needs. The need to receive healthcare away from home contributes to isolation, lack of support and limited resources. lthough methadone maintenance is considered the optimal treatment for opiate addiction in pregnancy, many of the remote communities lack access to methadone maintenance therapy and therefore women continue to struggle with opiate addiction throughout pregnancy re pregnant women from northern communities flown south for methadone maintenance treatment (MMT)? Currently there is no standard practice for those living in remote Northern communities. Some women relocate for MMT however housing and financial resources are a major concern for them. If the mother s urine tested positive for THC, what is your recommendation for breast feeding? Is it the mother s choice, taking into account the issues of socio-economic status (poverty and nutritional needs) and the lack of concise evidence about the risk to the baby? Breastfeeding is not recommended for women using illicit drugs until sobriety is reached therefore they should be advised to pump and discard their breast milk while they are using marijuana. Discussing this in the antenatal period is paramount so the woman can prepare to wean herself from illicit drug use. Periodic drug screening while the woman is breastfeeding is indicted to monitor for relapse. If a hospital has a pre-printed order set for the infant at risk for NS, does PCMCH recommend they change to a medical directive? medical directive is only one method to facilitate the timely collection of urine and meconium samples for toxicology screening for the infant with suspected or confirmed NS. Signed, pre-printed orders may also meet this need. Is there any time when urine or meconium testing can be done without consent? There is no clear legal opinion regarding consent for testing. Each hospital should follow their existing protocol for consent for testing urine and meconium. Hair testing requires consent. Is maternal consent required for testing? There is no clear opinion regarding consent for testing. Each hospital should follow their existing protocol for consent for testing urine and meconium. Hair testing requires consent. PCMCH has contacted the OH for advice regarding whether or not it is possible to have a single legal opinion for all Ontario hospitals regarding the consent issue. When do you suggest isolated hospitals initiate transfer of an infant with NS to a tertiary hospital? Transport should be initiated as soon as a baby at risk of NS is born if the isolated hospital is not in a position to care for the infant. What is the recommended first choice of treatment for polydrug withdrawal, phenobarb or Neonatal bstinence Syndrome Webinar (Feb. 9 & March 30, 2012): Questions & nswers Page 3 of 5

4 morphine? Q 21 Q 22 Q 23 Morphine should be considered the first line pharmacologic treatment of NS when supportive measures fail to adequately ameliorate the signs of withdrawal. Has there been research into the validity of the Finnegan Scoring system for older infants? In 2009, Jansson et al identified that older infants may have shorter periods of sleep than newborns. However they are capable of maintaining a quiet alert state. The study recommended that time spent in a quiet and organized state be included in total sleep for that scoring interval. Is it beneficial for the infant with NS to room-in with the mother? Rooming-in is beneficial and should be encouraged as it supports the practice of mother-baby dyad care. When pharmacological treatment is necessary transfer to the Special Care Nursery/NICU is required. Parental involvement in care in the NICU/SCN should be encouraged and supported. Is it safe for substance using women to breastfeed? Breastfeeding is not recommended for women using illicit drugs until sobriety is reached. These women should pump and discard their breast milk to establish and maintain their milk supply. Occasional use of the following substances may be of concern and mothers who use these substances in short episodes should avoid breastfeeding temporarily during this time. Substances causing concern include ecstasy, crystal meth, amphetamines, cocaine and related stimulants, alcohol, opioids, benzodiazepines and cannabis. Q 24 Q 25 t what point is Phenobarb introduced? Phenobarb is introduced when withdrawal symptoms are not adequately controlled by Morphine. Some centres use Clonidine instead of Phenobarb. See Pharmacological Treatment Protocol When on Morphine how long to do you leave the baby on monitoring? Cardio-respiratory monitoring is recommended for all infants starting on morphine and is continued for 4 days and/or until the dose is reduced. Further monitoring should then be at the discretion of the responsible physician. The goal is to ensure that the doses are not increasing but are decreasing and/or stabilized. Q 26 Q 27 What does cardio-respiratory monitoring include? Cardio-respiratory monitoring includes heart rate and respiratory rate and excludes ECG and oxygen saturation Can cardio-respiratory monitoring be done outside the SCN/NICU setting? Yes, cardio-respiratory monitoring can be done in any setting where the nurses are competent in managing the care of an infant receiving morphine, including cardio-respiratory monitoring. paediatric unit is sometimes used as an alternative care setting. Neonatal bstinence Syndrome Webinar (Feb. 9 & March 30, 2012): Questions & nswers Page 4 of 5

5 Q 28 Q 29 Q 30 Q 31 Q 32 Is it necessary for all infants with NS to remain in hospital throughout the weaning process? Discharging the infant with NS home on morphine should only be undertaken if the clinical team is confident that the social risk is low, the infant is stable, and there is a clear and comprehensive plan for weaning the infant and planned supervision of the infant during weaning. When weaning from morphine, is the dose reduced by 10% of the total daily dose, or 10% of the original dose of morphine. The dose used to wean the infant from morphine is based on 10% of the total daily dose. See the NS Pharmacologic Treatment Protocol dosing guidelines. What role does public health play in the support of infants with NS and their family after discharge? Public Health, including Healthy Babies/Healthy Children and sexual health clinics, provides important support for substance using women during pregnancy as well as support for mothers, infants and their families post discharge. What is your definition of polydrug exposure? Polydrug exposure refers to exposure to more than one addictive drug or substance. Is there an information-sharing site to discuss dosing and length of stay data? re there any sites auditing the peak dose of Morphine? There is currently no such information site but CIHI continually collects data on the average LOS by site. review of practices across the province was carried out when the expert panel was convened but no information on peak doses was obtained. Individual hospitals are able to acquire their own data through chart audits or pharmacy records. Neonatal bstinence Syndrome Webinar (Feb. 9 & March 30, 2012): Questions & nswers Page 5 of 5

THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE

THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE THE OPIOID DEPENDENT MOTHER AND NEWBORN - AN UPDATE THE 6 TH ANNUAL IVEY SYMPOSIUM Ron Abrahams, Claudette Chase, Judy Desmoulin, Mel Kahan, David Knoppert, Gideon Koren, Laura Lyons, Alice Ordean, Henry

More information

NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome

NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome Meghan Howell, MD FAAP Assistant Professor of Pediatrics Clinical Director, Tulane NICU Graduate Clinic Tulane University School

More information

Brief History of Methadone Maintenance Treatment

Brief History of Methadone Maintenance Treatment METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what

More information

Referral to the Women s Alcohol and Drug Service (WADS) Procedure

Referral to the Women s Alcohol and Drug Service (WADS) Procedure 1. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral is taken and processed. This includes the referral for clinical care

More information

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015

Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Objectives Discuss the current scope of maternal substance use and abuse List examples

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

Referral to the Women s Alcohol and Drug Service (WADS) Procedure

Referral to the Women s Alcohol and Drug Service (WADS) Procedure Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral

More information

Opioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome

Opioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome Opioid Use Disorder in Pregnancy Neonatal Abstinence Syndrome Opioid Use Disorder and Pregnancy Cont. 4.6 million women (or 3.8 percent) ages 18 and older misused prescription drugs in 2013. One-third

More information

Effects of Prenatal Illicit Drug. Use on Infant and Child

Effects of Prenatal Illicit Drug. Use on Infant and Child Effects of Prenatal Illicit Drug Use on Infant and Child Development Andrew Hsi, MD, MPH Larry Leeman, MD, MPH Family Medicine MCH Grand Rounds 6 July 2011 Objectives for Presentation At the end of this

More information

Opioid use in pregnancy and Neonatal Abstinence Syndrome

Opioid use in pregnancy and Neonatal Abstinence Syndrome Opioid use in pregnancy and Neonatal Abstinence Syndrome Morissa Ladinsky, MD Assoc. Professor of Pediatrics Division of General Pediatrics and Adolescent Medicine UAB Objectives 1. Understand the magnitude,

More information

Safe Babies Foster Parent Training Program

Safe Babies Foster Parent Training Program Safe Babies Foster Parent Training Program Module 1: Introduction to the Safe Babies Program 1 Begin the process of group participation Learning outcomes Understand the purpose and origins of the Safe

More information

9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment

9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment Postpartum Counseling for Women in MAT Katie Clark MSPH, CSAC A little about Katie SUD and PH crossroads BA Health Arts and Sciences Goddard College MSPH MCH UNC Project Lazarus, Yale, CHER Solutions LLC

More information

Opioids in Pregnancy. Beyond to Baby GENERAL INFO

Opioids in Pregnancy. Beyond to Baby GENERAL INFO Opioids in Pregnancy and Beyond to Baby by Marcia W. VanVleet, MD, MPH Medical Director, Newborn Service Team, Women and Infants Hospital, and Assistant Professor of Pediatrics, Brown Alpert Medical School,

More information

The Opioid-Exposed Woman

The Opioid-Exposed Woman The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus

More information

Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance

Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical

More information

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home

More information

Objectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016

Objectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016 Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute

More information

Managing drug misuse in pregnancy and beyond

Managing drug misuse in pregnancy and beyond Managing drug misuse in pregnancy and beyond Dr Emily Finch Clinical Director Addictions CAG, South London and Maudsley Foundation NHS Trust Rachel Evans, Adfam 1 / Aims of the session Update on management

More information

Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center

Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center NSDUH, 2012 National Survey on Drug Use and Health: 2012 Substance abuse: Public Health Problem

More information

Methadone and Pregnancy

Methadone and Pregnancy Methadone and Pregnancy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Charissa Patricelli, MD, CCFP, ABAM Clinical Associate Professor, Dept. of Family Practice UBC American Board of Addiction Medicine

More information

Buprenorphine & Controlled Substance Treatment Agreement

Buprenorphine & Controlled Substance Treatment Agreement Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a

More information

Counseling Guidelines: Breastfeeding and Maternal Alcohol, Tobacco and Other Drug Use

Counseling Guidelines: Breastfeeding and Maternal Alcohol, Tobacco and Other Drug Use Counseling Guidelines: Breastfeeding and Maternal Alcohol, Tobacco and Other Drug Use May 2008 These guidelines were developed by the Sonoma County Breastfeeding Coalition and the Sonoma County Perinatal

More information

Neonatal Abstinence Syndrome

Neonatal Abstinence Syndrome 5 Neonatal Abstinence Syndrome Amy P. Holmes, PharmD Introduction Neonatal abstinence syndrome (NAS) is recognized as the effect of intrauterine exposure to substances that can cause physical dependence.

More information

Neonatal Abstinence Syndrome (NAS)

Neonatal Abstinence Syndrome (NAS) Neonatal Abstinence Syndrome (NAS) Jodi Jackson, MD Neonatologist Children's Mercy Hospital Associate Professor of Pediatrics University of Missouri-Kansas City School of Medicine Medical director NICU

More information

Tobacco Use and Reproductive Health: An Update

Tobacco Use and Reproductive Health: An Update Project with Alberta Health Services Christene Fetterly Gail Foreman and Tasha Allen Tobacco Use and Reproductive Health: An Update Lorraine Greaves PhD Nancy Poole PhD Natalie Hemsing, Research Associate,

More information

Talking with your doctor

Talking with your doctor SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may

More information

Neonatal Abstinence: The epidemic Its Impact on All of Us

Neonatal Abstinence: The epidemic Its Impact on All of Us Neonatal Abstinence: The epidemic Its Impact on All of Us Michelle Bode MD, MPH Neonatologist Crouse Hospital Assistant Professor Pediatrics SUNY Upstate Objectives & Disclosure Statement 1) The participant

More information

8/24/2015 ADDICTION AND PREGNANCY. Fear ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY

8/24/2015 ADDICTION AND PREGNANCY. Fear ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION AND PREGNANCY L y n é e B r o w n, M A, C D P & D o n n a L i v i n g s t o n, R N A D A P T E D F R O M J i m W a l s h, M D Objectives: Recognize common fears and myths associated with substance

More information

Medication-Assisted Treatment & Pregnancy. Dave Kneessy, MS, MAC, CAP, LMHC Regional Director Central Florida Treatment Centers

Medication-Assisted Treatment & Pregnancy. Dave Kneessy, MS, MAC, CAP, LMHC Regional Director Central Florida Treatment Centers Medication-Assisted Treatment & Pregnancy Dave Kneessy, MS, MAC, CAP, LMHC Regional Director Central Florida Treatment Centers Addiction/ Substance Use Disorder Addiction is a Biopsychosocial Disease Has

More information

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to

More information

Emerging Populations: Challenges for the Early Childhood System. Presented by Maureen Greer

Emerging Populations: Challenges for the Early Childhood System. Presented by Maureen Greer Emerging Populations: Challenges for the Early Childhood System Presented by Maureen Greer Early Intervention/Early Childhood Special Interest Group (EIEC SIG) Webinar Series September 26, 2017 Presenter

More information

Medication for the Treatment of Addiction (MAT)

Medication for the Treatment of Addiction (MAT) Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication

More information

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons Marianna Corona Jennifer Foley September 12, 2017 Learning Objectives 2017 Improving Family Outcomes

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference Ministry of Health and Long-Term Care Presentation to the CPSO Methadone Prescribers Conference November 9, 2012 Overview Minister s Expert Working Group on Narcotic Addiction OxyNEO and OxyContin: Changes

More information

How do premature babies exposed to opiates in utero withdraw? Niroshini Perera

How do premature babies exposed to opiates in utero withdraw? Niroshini Perera How do premature babies exposed to opiates in utero withdraw? A comparison of withdrawal symptoms in preterm and term babies exposed to opiates in utero. Niroshini Perera Submitted in total fulfilment

More information

ADDICTION IN PREGNANCY

ADDICTION IN PREGNANCY ADDICTION IN PREGNANCY R. Corey Waller MD, MS, DFASAM Sr. Medical Director, Education and Policy The National Center for Complex Health and Social Needs DISCLOSURES No relevant disclosures OBJECTIVES The

More information

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. 201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. RELATES TO: KRS 311.530-311.620, 311.990 STATUTORY AUTHORITY: KRS

More information

Clinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP

Clinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP Clinical Management of Neonatal Abstinence Syndrome Tricia L. Romesberg, DNP, MSN, ARNP, CNNP Timeline Incidence of NAS Healthcare Cost and Utilization Project (HCUP), 1999-2013 State Inpatient Databases

More information

Neonatal abstinence syndrome

Neonatal abstinence syndrome PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Neonatal Abstinence Syndrome. These podcasts are designed to give medical students an overview of key topics in pediatrics.

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

Neonatal Drug Withdrawal

Neonatal Drug Withdrawal History Neonatal Drug Withdrawal Katherine Wang, MD, FAAP Avera McKennan Children s Hospital NICU Morphine has been used for pain for many years Congenital morphinism was not recognized as an entity until

More information

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place

More information

Methadone Maintenance 101

Methadone Maintenance 101 Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms

More information

Outcomes of Infants with Neonatal Abstinence Syndrome

Outcomes of Infants with Neonatal Abstinence Syndrome Outcomes of Infants with Neonatal Abstinence Syndrome Caroline O. Chua, MD, FAAP Medical Director, Division of Neonatology Director, Neonatal Follow Up Clinic Nemours Children s Hospital Orlando, Florida

More information

Opiate Use in Reproductive Age Females

Opiate Use in Reproductive Age Females Opiate Use in Reproductive Age Females February 15, 2017 2:00 pm-3:00 pm ET In order to hear the presentation please call +1 (562) 247-8422, access code 579-542-512 All Participant Phone Lines are Muted

More information

Running head: NEONATAL ABSTINENCE SYNDROME 1

Running head: NEONATAL ABSTINENCE SYNDROME 1 Running head: NEONATAL ABSTINENCE SYNDROME 1 Nursing Treatment of Neonatal Abstinence Syndrome Ferris State University Kelly Geraghty, Tracy James, Kristen Lintjer, Sara Potes, Rikki Zissler NEONATAL ABSTINENCE

More information

Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)

Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS) University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2014 Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS) Michael

More information

Multidisciplinary Management of the Opioid Crisis To Optimize Perinatal Outcome in a Rural Women s Clinic Population

Multidisciplinary Management of the Opioid Crisis To Optimize Perinatal Outcome in a Rural Women s Clinic Population Multidisciplinary Management of the Opioid Crisis To Optimize Perinatal Outcome in a Rural Women s Clinic Population Dale Robinson MD,FACOG Jennifer Gonzalez RN,BSN Surgeon General s Report 2016 Office

More information

Addiction and Pregnancy. Jim Walsh, MD Medical Director Addiction Recovery Service Swedish Medical Center WSADCP October 2018

Addiction and Pregnancy. Jim Walsh, MD Medical Director Addiction Recovery Service Swedish Medical Center WSADCP October 2018 Jim Walsh, MD Medical Director Addiction Recovery Service Swedish Medical Center WSADCP October 2018 Fear Shame Commitment Barriers Opportunities Fear Thalidomide induced phocomelia 1957 Fear Fetal Alcohol

More information

Marijuana in the Obstetric Population

Marijuana in the Obstetric Population Marijuana in the Obstetric Population Brittany MacGregor PGY 1 on behalf of Sophia Lenson PGY 3, Queens OB/Gyn Objectives 1. Review the status of legalization of cannabis products in Canada and the potential

More information

Child Welfare and MOMS: Building Partnerships to Improve Care

Child Welfare and MOMS: Building Partnerships to Improve Care Child Welfare and MOMS: Building Partnerships to Improve Care Goals Develop collaborative partnerships between MOMS pilot sites and child welfare agencies: Facilitate successful outcomes for clients Jointly

More information

Ohio Perinatal Quality Collaborative

Ohio Perinatal Quality Collaborative Ohio Perinatal Quality Collaborative Neonatal Abstinence Syndrome Project Presented by Michele Walsh MD Neonatal Lead Physician December 2017 Disclosure I have no financial or other conflicts of interest.

More information

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED

More information

Understanding Prenatal Drug Exposure

Understanding Prenatal Drug Exposure Understanding Prenatal Drug Exposure Prenatal Drug Exposure A mother s drug use hurts her unborn baby. Slide 2 Drug Categories Part 1 Prescription drugs: Prescribed by a doctor and used under a health

More information

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare

More information

Buprenorphine in Pregnancy: The Basics

Buprenorphine in Pregnancy: The Basics + Buprenorphine in Pregnancy: The Basics 1 Dr. Suzanne Turner & Dr. Lisa Graves Department of Family & Community Medicine St. Michael s Hospital, Toronto, ON + Mitigating Potential Bias 2 We have no financial

More information

Funding for TIPS provided by: The State of Tennessee Portions of this presentation 2002 The American College of Obstetricians and Gynecologists

Funding for TIPS provided by: The State of Tennessee Portions of this presentation 2002 The American College of Obstetricians and Gynecologists A training offered by Dr. Beth Bailey, Associate Professor of Family Medicine, East Tennessee State University; and by the Tennessee Intervention for Pregnant Smokers (TIPS) Program Funding for TIPS provided

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works

Johann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a

More information

The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital

The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital Volume 3 Issue 3 Article 10 2017 The Impact of Neonatal Abstinence Syndrome: The View from a Rural Kentucky Hospital Sydni Fazenbaker Crowell, Allison M. Crump-Rogers, William Crump, and LeAnn Langston

More information

Supersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required

Supersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required Effective Date 12/13/16 Neonatal Abstinence Syndrome (NAS) Date Approved 12/13/16 Guideline Pharmacologic Protocol Supersedes Date None and Management Guidelines Originating Dept. NICU Document Owner Dir.,

More information

2/28/2017. Substance Use Disorders + Pregnancy. Substance Use Disorders + Pregnancy. + Prevalence of the Problem

2/28/2017. Substance Use Disorders + Pregnancy. Substance Use Disorders + Pregnancy. + Prevalence of the Problem Substance Use Disorders Pregnancy Laura Lander, MSW, LICSW, Assistant Professor Department of Behavioral Medicine and Psychiatry, WVU Celebrating Connections Conference - April 2017 Substance Use Disorders

More information

... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot

... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot Department of... Health Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN Overview and Regional Snapshot Cynthia C. Thomas, DO, MPH, Assistant Health Officer, Northeast Regional Health

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among

More information

NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE

NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE Salma Ali MD, Debra Brendel RN, BSN, MSN and Ona Fofah MD Division of Neonatology and Newborn Medicine Department of

More information

SERVING SUBSTANCE EXPOSED NEWBORNS IN HARFORD COUNTY

SERVING SUBSTANCE EXPOSED NEWBORNS IN HARFORD COUNTY SERVING SUBSTANCE EXPOSED NEWBORNS IN HARFORD COUNTY A Snapshot of the Data, Services, and Outcomes Jerome M. Reyerson, LCSW-C Director, Harford County Department of Social Services GLIMPSE OF A SUBSTANCE

More information

Neonatal Abstinence Syndrome:

Neonatal Abstinence Syndrome: Neonatal Abstinence Syndrome: Reconsidering the Standard Approach Matthew Grossman, M.D. Assistant Professor of Pediatrics Yale School of Medicine Quality and Safety Officer Yale-New Haven Children s Hospital

More information

HARM REDUCTION & TREATMENT. Devin Reaves MSW

HARM REDUCTION & TREATMENT. Devin Reaves MSW HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that

More information

Many drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age.

Many drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age. 1 Chapter 12 Section 1 Objectives List six ways illegal drug use can be dangerous. State five reasons a person might try illegal drugs. Identify the reason drug abuse is especially dangerous to teens.

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Care of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?

Care of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome? Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute

More information

Clinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13

Clinical Policy: Neonatal Abstinence Syndrome Guidelines Reference Number: CP.MP.86 Effective Date: 10/13 Clinical Policy: Reference Number: CP.MP.86 Effective Date: 10/13 Last Review Date: 10/17 See Important Reminder at the end of this policy for important regulatory and legal information. Revision Log Description

More information

Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD

Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD 1 The National Academies of Sciences, Engineering and Medicine Regulatory Strategies of address prescription opioidrelated harms 4 th of November, 2016 Washington DC Product Labeling to Communicate Benefits

More information

Child Welfare and Substance Abuse. Erica Tarasovitch, MSW Central Florida Behavioral Health Network

Child Welfare and Substance Abuse. Erica Tarasovitch, MSW Central Florida Behavioral Health Network Child Welfare and Substance Abuse Erica Tarasovitch, MSW Central Florida Behavioral Health Network Parental Substance Use Marijuana was the most commonly used illicit drug in 2006, accounting for 72.8

More information

Depression in Pregnancy

Depression in Pregnancy TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date

More information

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING Opioid Use Disorder in Pregnancy 2017 Recommendations from ACOG and The Pew Charitable Trust KATHY D. HARTKE, MD, LEGISLATIVE CO-CHAIR AND IMMEDIATE PAST CHAIR, WISCONSIN SECTION OF THE AMERICAN COLLEGE

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Does ultram show up as an opiate

Does ultram show up as an opiate Search Does ultram show up as an opiate Tramadol ( Ultram ) is prescribed for treating moderate to severe pain in adults. 19-2-2018 I took Tramadol Hydrochloride for 6 months due to joint pain from my

More information

Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients

Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients Press release Orexo completes 1,080 patient REZOLV study and reports on improved treatment of opioid dependent patients Uppsala, Sweden, September 2, 2016 Orexo AB (publ.) announces that the REZOLV retrospective

More information

Neonatal Abstinence Syndrome

Neonatal Abstinence Syndrome Neonatal Abstinence Syndrome TAMARA HARVANKO RN, BAN HIGH RISK OB CARE COORDINATOR CASE MANAGEMENT HENNEPIN COUNTY MEDICAL CENTER TAMARA.HARVANKO@HCMED.ORG 612-873-6552 https://www.youtube.com/watch?v=tk2hoyupkvi

More information

Substance use and misuse

Substance use and misuse An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes

More information

Neonatal Abstinence Syndrome: Focus on Prevention and Role of Collaboratives

Neonatal Abstinence Syndrome: Focus on Prevention and Role of Collaboratives Neonatal Abstinence Syndrome: Focus on Prevention and Role of Collaboratives Brevard County Health Department Melbourne, FL April 7, 2017 Mark L. Hudak, MD Professor and Chairman of Pediatrics University

More information

Neonatal Abstinence Syndrome:

Neonatal Abstinence Syndrome: Neonatal Abstinence Syndrome: Rethinking Our Approach Matthew Grossman, M.D. Assistant Professor of Pediatrics Yale School of Medicine Quality and Safety Officer Yale-New Haven Children s Hospital Patrick,

More information

Treating Opioid Use Disorders: An Update for Counselors and Other Providers

Treating Opioid Use Disorders: An Update for Counselors and Other Providers Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL

More information

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine

Opioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine Opioid Use Disorders and Pregnancy Marcela Smid, MD Maternal-Fetal Medicine UNIVERSITY OF UTAH HEALTH, 2017 OBJECTIVES Definitions Epidemiology Pharmacology Effects on pregnancy Screening Treatment CARE

More information

The Substance Exposed Newborn Alphabet Soup

The Substance Exposed Newborn Alphabet Soup The Substance Exposed Newborn Alphabet Soup SEN, NAS, NOWS, OUD, SUD & MAT Sara Park MD Chief Medical Officer Comprehensive Medical and Dental Program Department of Child Safety CAP conference, July 2017

More information

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic

More information

Overview of Opiate Addiction

Overview of Opiate Addiction Overview of Opiate Addiction Conflict of interest 2 talks for Purdue about dangers of opioid addiction Bias support patients in both abstinence and methadone but seeing more stability on MMT Opioid Addiction

More information

When you drink, your baby drinks too. Drinking alcohol during

When you drink, your baby drinks too. Drinking alcohol during Alcohol and Pregnancy Don t Mix When you drink, your baby drinks too. Drinking alcohol during pregnancy could cause your baby to be born with Fetal Alcohol Spectrum Disorder (FASD) or other alcohol-related

More information

PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN

PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN 1 OPIOID USE DISORDER IN WOMEN Recognition & Prevention Date: August 14 th, Time: 8 am Presenters: Deepa Nagar MD, Andria Peterson PharmD Maternal Treatment

More information

Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health

Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health Columbus, Ohio Assignment Description The rapid advance of the opiate crisis has had far

More information

INTERVENTIONS TO SUPPORT BREASTFEEDING IN WOMEN ON OPIOID MAINTENANCE THERAPY: A SYSTEMATIC REVIEW. Meg Doerzbacher RN, MS, NNP-BC

INTERVENTIONS TO SUPPORT BREASTFEEDING IN WOMEN ON OPIOID MAINTENANCE THERAPY: A SYSTEMATIC REVIEW. Meg Doerzbacher RN, MS, NNP-BC INTERVENTIONS TO SUPPORT BREASTFEEDING IN WOMEN ON OPIOID MAINTENANCE THERAPY: A SYSTEMATIC REVIEW Meg Doerzbacher RN, MS, NNP-BC 1 Background Increased prevalence of opioid use disorder Increased incidence

More information

INTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia

INTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia The American Journal on Addictions, 27: 92 96, 2018 Copyright 2018 American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/ajad.12687 Brief Report: Treating Women

More information

What To Expect. Maternal Cannabis Use during Pregnancy and the Impacts on Offspring

What To Expect. Maternal Cannabis Use during Pregnancy and the Impacts on Offspring www.ccsa.ca www.cclt.ca What To Expect Maternal Cannabis Use during Pregnancy and the Impacts on Offspring Presentation for: 2016 Best Start Conference Amy Porath-Waller, PhD Katie Fleming, MA February

More information

Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention

Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention Cynthia Thomas, DO,MPH Northeast Regional Health Office Tennessee Department of Health Disclosure Statement of Financial

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

Substance-Exposed Newborn

Substance-Exposed Newborn Substance-Exposed Newborn Definition: Substance-exposed newborn as a maltreatment occurs when a child is exposed to a controlled substance or alcohol prenatally. Exposure to a controlled substance or alcohol

More information

Emergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC

Emergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC Emergent Issues Affecting Early Intervention/ Early Childhood Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC Conversation Points Changing Demographics Emergent Trends

More information